Markets
Supporters of both parties exchange words outside CBS Studios ahead of the vice-presidential debate between Gov. Tim Walz (D) and Sen. JD Vance (R-Ohio)
Supporters of Trump/Vance display their sign as a Harris/Walz bus drives past (Ricky Carioti/Getty Images)
Indecision 2024

Massive divergence between US stocks and the stock market’s “fear gauge” as election looms

Traders are taking out insurance against a market-unfriendly result to the November 5 vote even as stocks continue to climb to fresh records.

Luke Kawa
10/14/24 9:54AM

The US election is creating a big disconnect between the performance of the S&P 500 and traders’ most popular gauge for assessing the level of worry among market participants: the VIX.

Typically, when the S&P 500 Index has made an all-time high, the VIX Index — the expected volatility of the benchmark gauge over the next 30 days, often called the market’s “fear gauge” — is at 13.5. Last week, the VIX ended above 20 twice while US stocks set fresh records.

Only 12% of S&P 500 record closes saw a higher VIX than Friday’s close. Nearly all of these instances were during the dot-com bubble or the market’s rapid reclamation of all-time highs after the pandemic struck, though mass uncertainty still reigned over when we’d see life return to normal.

The VIX Index is based on one-month options prices. Usually, its expectations are somewhat extrapolative, hinging on recent history. That is, if the market just had a big down day, people will be more concerned about the potential for the beatings to continue until morale improves. Vice versa if there’s been smooth sailing recently.

Currently, the realized volatility of the S&P 500 over the past month is 10.1 — low by historical standards. High implied volatility right now is not based on extrapolative expectations, but rather, it’s effectively a function of traders taking out insurance, as the results of the election might prove unsettling to the stock market.

“Looking out over the next few weeks, however, the vol premium for the US election is likely to keep moving higher as it has in prior elections,” wrote Deutsche Bank strategists led by Parag Thatte.

Of course, it’s notoriously difficult to say what kind of election outcome would cause the most knee-jerk negative response in markets, or when political changes really leave a market imprint. US equity futures dived as the 2016 election results showed a surprising victory for President Donald Trump, only to turn around and scream higher as traders decided that a world of tax cuts wouldn’t be the worst thing for corporate America and could outweigh any potential negatives. 

Stocks performed well after the 2020 results. But what really began to kick off volatility in the bond market was the run-off Senate election in early 2021 that gave Democrats full control of both legislative bodies of Congress and made it easier to increase government spending.

Dennis DeBusschere, 22V Research chief market strategist, reckons that a divided government will be the most market-friendly outcome for the November 5 vote.

“An orderly election, no sweep, and continued strong economic growth would reduce tail risk concerns, supporting lower implied vol, a risk-on rotation, and higher markets in the final months of 2024,” he wrote.

On that front, expectations are about as much of a coin flip as for the presidential election itself — at least according to betting markets. On Kalshi, the cumulative probability of a Republican or Democratic sweep is marginally higher than any divided-government result.

And while it’s not the usual state of affairs, we do have some historical precedents for US stocks and implied volatility moving higher in tandem. John Kolovos, chief technical strategist at Macro Risk Advisors, likened the current setup in stocks to the mid-’90s, when Federal Reserve interest-rate cuts helped the economy achieve a soft landing and the S&P 500 and the VIX Index proceeded to trend upward.

“I remember this old saying: you can have a low-vol bull market, you can have a high-vol bull market, but you can never have a low-vol bear market,” he said.

More Markets

See all Markets
markets

GameStop can’t stop winning, on track for longest streak of gains since 2022

Unless we jinx it, GameStop is poised for its longest winning streak since 2022, with shares up 3% as of 2:04 p.m. ET.

The video game and collectibles retailer hasn’t posted a down day since September 4 and is poised for its eighth consecutive day of gains. Shares are up nearly 18% over this period, versus a 1.6% advance for the S&P 500.

The bulk of these gains came in the wake of the company’s stellar second-quarter earnings report, which exceeded expectations on the top and bottom lines as well as marking the fifth consecutive quarter of positive operating cash flow generation for the first time in its history.

Including this one, the company has posted eight or more consecutive days of gains on 25 occasions during its history as a publicly traded company.

Its last seven-session winning streak came in mid-July of last year, about a month after Keith Gill (aka Roaring Kitty) disappeared from the scene after his brief reappearance, as part of a relatively violent market rotation into small-cap stocks.

markets

Nio surges to an 11-month high following an upgrade from UBS ahead of its new SUV launch

Chinese EV maker Nio is climbing for the fourth straight trading day, following an upgrade from UBS to buy from neutral. Nio’s nearly 7% jump propelled the stock to its highest level since last October.

UBS also bumped its price target for Nio up to $8.50, a 37% hike.

Nio will begin deliveries of its new ES8 SUV this weekend, priced to compete with Tesla’s Model Y. Last week, the EV maker said it planned to raise up to $1 billion on a share offering.

According to UBS analyst Paul Gong, Nio’s latest products “could further attract consumers after the US $1 billion equity offerings strengthened visibility on its healthy operations.”

markets

Moderna is up on the release of positive results for reformulated Covid vaccine

Moderna rose on Tuesday after it announced encouraging trial results for its next COVID-19 vaccine.

The data from its phase 4 clinical trial showed the 2025-26 formula of its COVID-19 vaccine, which targets a new variant and was recently approved by the FDA with some limitations, produced a strong immune response among people ages 12 through 64. Covid vaccine sales account for virtually all of Modernas revenue.

The company has had a tumultuous year as the Trump administration makes moves to limit who is able to access the vaccine. Last month, the FDA limited approval for the coronavirus vaccine to higher-risk populations; previously, anyone older than 6 months was eligible for it.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.